In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease

Journal of Neuroscience Methods

Volumn 188, Issue 1, 2010, Pages 151-164

  Yeager, Matthew P ^a   Coleman, Randolph A ^a  

^a The College of William and Mary   (United States)

Author keywords

Synuclein aggregation; Computational biology; Glutathione system; Labile iron; Lewy bodies; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; COPPER; GLUTATHIONE; IRON;

ARTICLE; CONCENTRATION RESPONSE; DEGRADATION; DISEASE PREDISPOSITION; DOPAMINE METABOLISM; GENE MUTATION; HOMEOSTASIS; LIPID PEROXIDATION; LYSOSOME; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MISSENSE MUTATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; BRAIN; COMPUTER SIMULATION; COPPER; DOPAMINE; GLUTATHIONE; HUMANS; IRON; MODELS, NEUROLOGICAL; MUTATION; NEURONS; PARKINSON DISEASE;

EID: 77950461488     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.01.034     Document Type: Article

References (146)

1. Arreguin S., Nelson P., Padway S., Shirazi M., Pierpont C. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease. J Inorg Biochem 2009, 103:87-93.
2. Asanuma M., Miyazaki I., Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003, 5:165-176.
3. Barnham K.J., Bush A.I. Metals in Alzheimer's and Parkinson's disease. Curr Opin Chem Biol 2008, 12:222-228.
4. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Gen 1999, 8:711-715.
5. Berg D., Youdim M.B.H. Role of iron in neurodegenerative disease. Top Magn Reson Imaging 2006, 17:5-17.
6. Berg D., Gerlach M., Youdim M.B.H., Double K.L., Zecca L., Riederer P., et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001, 79:225-236.
7. Berg D., Hochstrasser H., Scweitzer K.J., Riess O. Disturbance of iron metabolism in Parkinson's disease-ultrasonography as a biomarker. Neurotox Res 2006, 9:1-13.
8. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
9. Beutler E. "Pumping" iron: the proteins. Science 2004, 306:2051-2053.
10. Bharucha K.J., Friedman J.K., Vincent A.S., Ross E.D. Lower serum ceruloplamsin correlate with younger age of onset in Parkinson's disease. J Neurol 2008, 255:1957-1962.
11. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 229:256-259.
12. Borie C., Gasparini F., Verpillat P., Bonnet A.M., Agid Y., Hetet G., et al. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 2002, 249:801-804.
13. Bové J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRX 2005, 2:484-494.
14. Caudle W.M., Colebrooke R.E., Emson P.C., Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 2008, 31:303-308.
15. Chartier-Harlin M.-C., Kachergus J., Rournier C., Mouroux V., Douay X., Lincoln S., et al. α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
16. Chesselet M.-F. In vivo α-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp Neurol 2008, 209:22-27.
17. Choi S.Y., Kwon H.Y., Kwon O.B., Eum W.S., Kang J.H. Fragmentation of human ceruloplasmin induced by hydrogen peroxide. Biochimie 2000, 82:175-180.
18. Cole N.B., Murphy D.D., Lebowitz J., Di Noto L., Levine R.L., Nussbaum R.L. Metal-catalyzed oxidation of α-synuclein: helping to define the relationships between oligomers, protofibrils, and filaments. J Biol Chem 2005, 280:9678-9690.
19. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med 1998, 4:1318-1320.
20. Conway K.A., Harper J.D., LansburyF P.T. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease. Biochemistry 2000, 39:2552-2563.
21. Conway K.A., Lee S.-J., Rochet J.-C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000, 97:571-576.
22. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
23. Dexter D.T., Wells F.R., Lee A.J., Agid F., Agid Y., Jenner P., et al. Increased nigral iron content and alterations in other meral ions occurring in brain in Parkinson's disease. J Neurochem 1989, 52:1830-1836.
24. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990, 55:16-20.
25. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
26. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994, 9:92-97.
27. Dunn L.L., Rahmanto Y.S., Richardson D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2006, 17:93-100.
28. Eliezer D., Kutluay E., Bussell R., Browne G. Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol 2001, 307:1061-1073.
29. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006, 7:306-318.
30. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., et al. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Gen 2001, 10:1847-1851.
31. Farrer M.J., Kachergus J., Forno L., Lincoln S., Wang D.-S., Hulihan M., et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol 2004, 55:174-179.
32. Faucheux B.A., Bonnet A.M., Agid Y., Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
33. Fernagut P.O., Chesselet M.-F. α-Synuclein and transgenic mouse models. Neurobiol Dis 2004, 17:123-130.
34. Fleming S.M., Fernagut P.O., Chesselet M.-F. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRX 2005, 2:495-503.
35. Gaggelli E., Kozlowski H., Valensin D., Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, Prior, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006, 106:1995-2044.
36. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab 2005, 1:155-157.
37. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J Neurochem 1994, 63:793-807.
38. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild type human α-synuclein assemble into elongated filaments with distinct morphologies. J Biol Chem 1999, 274:7619-7622.
39. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M.-Y. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002, 34:521-533.
40. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
41. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997, 48:650-658.
42. Goswami T., Rolfs A., Hediger M.A. Iron transport: emerging roles in health and disease. Biochem Cell Biol 2002, 80:679-689.
43. Greenbaum E.A., Graves C.L., Mishizen-Eberz A.J., Lupoli M.A., Lynch D.R., Englander S.W., et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J Biol Chem 2006, 280:7800-7807.
44. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease: an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999, 122:667-673.
45. Gu M., Owen A.D., Toffa S.E.K., Cooper J.M., Dexter D.T., Jenner P., et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 1998, 158:24-29.
46. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 1999, 10:717-720.
47. Hentze M.W., Muchthaler A.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
48. Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004, 63:1912-1917.
49. Hochstrasser H., Tomiuk J., Uwe W., Behnke S., Spiegel J., Krüger R., et al. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J 2005, 19:1851-1853.
50. Ibáñez P., Bonner A.-M., Lohmann E., Tison F., Pollak P., Agid Y. Causal relations between α-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
51. Jenner P., Olanow C. Understanding cell death in Parkinson's disease. Ann Neurol 1998, 44:S72-S84.
52. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 1998, 273:26292-26294.
53. Jiménez I., Gotteland M., Zarzuelo A., Uauy R., Speisky H. Loss of the metal binding properties of metallothionein induced by hydrogen peroxide and free radicals. Toxicology 1997, 120:37-46.
54. Johnson C.C., Gorell J.M., Rybicki B.A., Sanders K., Peterson E.L. Nutrient intake as a risk factor for Parkinson's disease. Int J Epdiemiol 1999, 28:1102-1109.
55. Kahle P.J., Neumann M., Ozmen L., Müller V., Jacobsen H., Schindzielorz A., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci 2000, 20:6365-6373.
56. Kahle P.J., Haass C., Kretzschmar H.A., Neumann M. Structure/function of α-synuclein in health and disease: rational development of animal models for Parkinson's and related disease. J Neurochem 2002, 82:449-457.
57. Kaushik P., Gorin F., Vali S. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comput Neurosci 2007, 22:147-160.
58. Kim K.S., Choi S.Y., Kwon H.Y., Won M.H., Kang T.C., Kang J.H. The ceruloplasmin and hydrogen peroxide system induces α-synuclein aggregation in vitro. Biochemie 2002, 84:625-631.
59. Kirik D., Björklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 2003, 26:386-392.
60. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka M., et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J Neurosci 2002, 22:2780-2791.
61. Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P α-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 2002, 20:605-612.
62. Koeppen A.H. The history of iron in the brain. J Neurol Sci 1995, 134(Suppl.):1-9.
63. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
64. Krüger R., Vieira-Saecker A.M., Kuhn W., Berg D., Muller T., Kühnl N., et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann Neurol 1999, 45:611-617.
65. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003, 531:81-92.
66. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., et al. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002, 322:1089-1102.
67. Lauwers E., Bequé D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., et al. Non-invasive imaging in neuropathology in a rat model of α-synuclein overexpression. Neurobiol Aging 2007, 28:248-257.
68. Lecca P. In Silico experiments on a faulty ubiquitin-proteasome system in the pathogenesis of Parkinson's disease. Online J Bioinform 2008, 9:30-43.
69. Lee J., Prohaska J.R., Thiele D.J. Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. PNAS 2001, 98:6842-6847.
70. Lee H.J., Shin S.Y., Choi C., Lee Y.H., Lee S.J. Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002, 277:5411-5417.
71. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002, 99:8968-8973.
72. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 2002, 99:10813-10818.
73. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci 2002, 3:932-942.
74. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
75. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001, 8:535-539.
76. McNaught K.S.P., Perl D.P., Brownell A.-L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004, 56:149-162.
77. Melrose H.L., Lincoln S.J., Tyndall G.M., Farrer M.J. Parkinson's disease: a rethink of rodent models. Exp Brain Res 2006, 173:196-204.
78. Mochizuki H., Yamada M., Mizuno Y. α-Synuclein overexpression model. J Neural Transm 2006, 70:281-284.
79. Moos T., Morgan E.H. Transferrin and transferrin receptor function in brain barrier system. Cell Mol Neurobiol 2000, 20:77-95.
80. Morita H., Ikeda S., Yamamoto K., Morita S., Yoshida K., Nomoto S., et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995, 37:646-656.
81. Mukhopadhyay C., Attieh Z.K., Fox P.L. Role of ceruloplasmin in cellular iron uptake. Science 1998, 279:714-717.
82. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., et al. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 1999, 274:9843-9846.
83. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulated iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
84. Nishioka K., Hayashi S., Farrer M.J., Singleton A.B., Yoshino H., Imai H., et al. Clinical heterogeneity of α-synuclein gene duplication in Parkinson's disease. Ann Neurol 2006, 59:298-309.
85. Oestreicher E., Sengstock G.J., Riederer P., Olanow C.W., Dunn A.J., Arendash G. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994, 660:8-18.
86. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144.
87. Orino K., Lehman L., Tsuji Y., Ayaki H., Torti S.V., Torti F.M. Ferritin and the response to oxidative stress. Biochem J 2001, 357:241-247.
88. Ortega R., Cloetens P., Devès G., Carmona A., Bohic S. Iron storage with dopamine neurovesicles reveled by chemical nano-imaging. PloS ONE 2007, 2:e925.
89. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000, 20:6048-6054.
90. Pals P., Lincoln S., Manning J., Heckman M., Skipper L., Hulihan M., et al. α-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 2004, 56:591-595.
91. Pandey N., Schmidt R.E., Galvin J.E. The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 2006, 197:515-520.
92. Peery G., Sayre L.M., Atwood C.S., Castellani R.F., Cash A.D., Rottkamp C.A., et al. The role of iron and copper in the aetiology of neurodegenerative disorders; therapeutic implications. CNS Drugs 2002, 16:339-352.
93. Peña M.M.O., Lee J., Thiele D.J. A delicate balance: homeostatic control of copper uptake and distribution. J Nutr 1999, 129:1251-1260.
94. Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., Feany M.B. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007, 27:3338-3346.
95. Petris M.J., Smith K., Lee J., Thiele D.J. Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem 2003, 278:9639-9646.
96. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutaton in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
97. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D., Checkoway H. Parkinson's disease risk associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003, 60:1761-1766.
98. Qi Z., Miller G.W., Voit E.O. Computational Systems Analysis of Dopamine Metabolism. PLoS ONE 2008, 3:e2444.
99. Raichur A., Vali S., Gorin F. Dynamic modeling of α-synuclein aggregation for the sporadic and genetic forms of Parkinsoin's disease. Neuroscience 2006, 142:859-870.
100. Rathke-Hartlieb S., Kahle P., Neumann M., Ozmen L., Haid S., Okochi M., et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J Neurochem 2001, 77:1181-1184.
101. Religa D., Strozyk D., Cherny R.A., Volitakis I., Haroutunian V., Winblad B., et al. Elevated cortical zinc in Alzheimer disease. Neurology 2006, 67:69-75.
102. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., et al. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 2002, 175:35-48.
103. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989, 52:515-520.
104. Rossi E. Hepcidin-the iron regulatory hormone. Clin Biochem Rev 2005, 26:47-49.
105. Rybicki B.A., Johnson C.C., Uman J., Gorell J.M. Parkinson's diseases mortality and the industrial use of heavy metals in Michigan. Mov Disord 1993, 8:87-92.
106. Salazar J., Mena N., Núñez M.T. Iron dyshomeostasis in Parkinson's disease. J Neural Transm 2006, 71:205-213.
107. Sass M.B., Lorenz A.N., Green R.L., Coleman R.A. A pragmatic approach to biochemical systems theory applied to an α-synuclein. J Neurosci Methods 2009, 178:366-377.
108. Savageau M.A. Biochemical systems analysis. I. Some mathematical properties of the rate law for the component enzymatic reactions. J Theor Biol 1969, 25:365-369.
109. Savageau M.A. Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. J Theor Biol 1969, 25:370-379.
110. Savageau M.A. Biochemical systems analysis. III. Dynamic solutions using a power-law approximation. J Theor Biol 1970, 26:215-226.
111. Schapira A.H.V. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008, 7:97-109.
112. Schlief M.L., Craig A.M., Gitlin J.D. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 2005, 25:239-246.
113. Sengstock G.J., Olanow C.W., Dunn A.J., Arendash G.W. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993, 35:67-82.
114. Sengstock G., Olanow C.W., Dunn A.J., Barone S., Arendash G. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 1994, 130:82-94.
115. Shang H.F., Jiang X.F., Burgunder J.M., Chen Q., Zhou D. Novel mutation in the ceruloplasmin gene causing a cognitive and movement disorder with diabetes mellitus. Mov Disord 2006, 21:2217-2220.
116. Sherer T.B., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative stress. J Neurosci 2002, 22:7006-7015.
117. Sherer T.B., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003, 23:10756-10764.
118. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994, 36:348-355.
119. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
120. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988, 74:199-205.
121. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998, 95:6469-6473.
122. Tan E.K., Matsuura T., Nagamitsu S., Khajavi M., Jankovic J., Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiological link with essential tremor?. Neurology 2000, 54:1195-1198.
123. Tchernitchko D., Bourgeois M., Martin M.E., Beaumont C. Expression of the two mRNA isoforms of the iron transporter Nrmap2/DMT1 in mice and function of them iron response element. Biochem J 2002, 363:449-455.
124. Temlett J.A., Landsberg J.P., Watt F., Grime G.W. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 1994, 62:134-146.
125. Theil E.C. Regulation of ferritin and transferrin receptor mRNAs. J Biol Chem 1990, 265:4771-4774.
126. Thiruchelvam M.J., Power J.M., Cory-Slechta D.A., Richfield E.K. Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice. Eur J Neurosci 2004, 19:845-854.
127. Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein (1-120): implications for Lewy body disorders. J Neurosci 2006, 26:3942-3950.
128. Toffa S., Kunikowska G.M., Zeng B.-Y., Jenner P., Marsden C.D. Chronic glutathione depletion in rat brain does not cause nigrostriatal pathway degradation. J Neural Transm 1997, 104:67-75.
129. Tórsdottir G., Kristinsson J., Sveinbjornsdóttir S., Snaedal J., Johannesson T. Copper, ceroluplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 1999, 85:239-243.
130. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrilliation of human α-synuclein. J Biol Chem 2001, 276:44284-44296.
131. Vali S., Mythri R.B., Jagatha B., Padiadpu J., Ramanujan K.S., Andersen J.K., et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007, 149:917-930.
132. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., et al. Neuropathology in mice expressing human α-synuclein. J Neurosci 2000, 20:6021-6029.
133. Voit E.O. Computational analysis of biochemical systems: a practical guide for biochemists and molecular biologists 2000, Cambridge University Press, New York.
134. Volles M.J., Lansbury P.T. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41:4595-4602.
135. Wakamatsu M., Ishii A., Ukai Y., Sakagami J., Ukai Y., Ono M., et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiol Aging 2008, 29:574-585.
136. Warner T.T., Schapira A.H.V. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003, 53:S16-S25.
137. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
138. Wolozin B., Golts N. Iron and Parkinson's disease. Neuroscientist 2002, 8:22-32.
139. Wüllner U., Löschmann P.-A., Schulz J.B., Schmid A., Dringen R., Eblen F., et al. Glutathione depletion potentiates MPTP and MPP+ neurotoxicity in nigral dopaminergic neurons. Neuroreport 1996, 7:921-923.
140. Xu J., Kao S.-Y., Lee F.J.S., Song W., Jin L.-W., Yankner B.A. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002, 8:600-606.
141. Xu J., Zhong N., Wang H., Elias J.E., Kim C.Y., Woldman I., et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Gen 2005, 14:1231-1241.
142. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004, 91:451-461.
143. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcnao E., Ros R., Ampuero I., et al. The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann Neurol 2003, 55:164-173.
144. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. PNAS 2004, 101:9843-9848.
145. Zecca L., Youdim M.B.H., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004, 5:863-873.
146. Zhou W., Freed C.R. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T α-synuclein toxicity. J Biol Chem 2005, 280:43150-43158.